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OBJECTIVE — Subjects with the metabolic syndrome have reduced HDL cholesterol con-
centration and altered metabolism of high-density lipoprotein (Lp)A-I and LpA-I:A-II particles.
In the metabolic syndrome, fenoﬁbrate and atorvastatin may have differential effects on HDL
particle kinetics.
RESEARCH DESIGN AND METHODS — Eleven men with metabolic syndrome were
studied in a randomized, double-blind, crossover trial of 5-week intervention periods with
placebo, fenoﬁbrate (200 mg/day), and atorvastatin (40 mg/day). LpA-I and LpA-I:A-II kinetics
were examined using stable isotopic techniques and compartmental modeling.
RESULTS — Compared with placebo, fenoﬁbrate signiﬁcantly increased the production of
both LpA-I:A-II (30% increase; P  0.001) and apoA-II (43% increase; P  0.001), accounting
for signiﬁcant increases of their corresponding plasma concentrations (10 and 23% increases,
respectively), but it did not alter LpA-I kinetics or concentration. Atorvastatin did not signiﬁ-
cantly alter HDL concentration or the kinetics of HDL particles.
CONCLUSIONS — In the metabolic syndrome, fenoﬁbrate, but not atorvastatin, inﬂuences
HDL metabolism by increasing the transport of LpA-I:A-II particles.
Diabetes Care 32:2111–2113, 2009
A
therogenic dyslipidemia, reﬂected
by elevated plasma triglyceride
and reduced HDL cholesterol
concentrations, is a cardinal feature of
the metabolic syndrome (1). Recent
ﬁndings from the Fenoﬁbrate Interven-
tion and Event Lowering in Diabetes
(FIELD) study demonstrated that meta-
bolic syndrome subjects with athero-
genic dyslipidemia had the highest risk
of cardiovascular disease (CVD) (2).
Disturbed metabolism of high-density
lipoprotein (Lp)A-I and LpA-I:A-II par-
ticles may partly account for the in-
creased risk of CVD (3).
In a previous study of 11 metabolic
syndrome subjects, we reported that fe-
noﬁbrate,butnotatorvastatin,hadsignif-
icant effects on HDL apolipoprotein
(apo)A-I kinetics (4). Given the differen-
tial role of LpA-I and LpA-I:A-II in re-
verse cholesterol transport (5), it is
important to elucidate the precise ef-
fects of these agents on HDL particle
kinetics. Using stored samples (4), we
extended this study by investigating the
effects of these agents on LpA-I and
LpA-I:A-II particle kinetics.
RESEARCH DESIGN AND
METHODS— Eleven nondiabetic
men with metabolic syndrome entered a
randomized, double-blind, placebo-
controlled, crossover trial, in which they
were randomized to a 5-week treatment
periodofeitherfenoﬁbrate(200mg/day),
atorvastatin (40 mg/day), or placebo. A
2-week washout phase was included at
the end of each treatment period. All sub-
jects provided written consent as ap-
proved by the ethics committee of the
South Eastern Sydney Area Health Ser-
vice. This clinical protocol, including ad-
ministration of [d3]-leucine and blood
sampling, has previously been described
(4).
Measurement of isotopic
enrichments and calculation of
kinetic parameters
HDL–apoA-I and –apoA-II were isolated
by ultracentrifugation and electrophore-
sis, delipidated, hydrolyzed, and derivat-
ized as previously described (6). Isotopic
enrichment was assessed using gas-
chromatography mass spectrometry with
selected ion monitoring of derivatized
samples. The SAAM II program (SAAM
Institute, Seattle, WA) was used to ﬁt the
model to the observed tracer-to-tracee ra-
tio data. The fractional catabolic rates
(FCRs) of apoA-I in LpA-I, LpA-I:A-II,
apoA-I, and apoA-II were derived from
the model parameters giving the best ﬁt.
The corresponding production rates were
calculatedastheproductofFCRandpool
size.
Plasma biochemistry
ApoA-I and apoA-II concentrations were
determined by immunonephelometry
(Dade Behring). ApoA-I concentration in
LpA-Iparticleswasmeasuredbydifferen-
tial electroimmuoassay (Sebia, Moulin-
eaux, France). ApoA-I concentration in
LpA-I:A-IIparticleswascalculatedastotal
apoA-I  apoA-I in LpA-I. As previously
described (4), plasma lipid and glucose
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matic methods. Plasma insulin was mea-
sured by radioimmunoassay. Insulin
resistance was estimated using the ho-
meostasis model assessment score.
Statistical analyses
Data at the end of the three treatment pe-
riods were compared using a mixed-
effects model (SAS Proc Mixed, SAS
Institute). To adjust for multiple compar-
isons across the three treatment periods,
we deﬁned statistical signiﬁcance at the
1.7% level.
RESULTS— The 11 subjects recruited
were middle-aged, centrally obese, nor-
motensive, dyslipidemic, and insulin re-
sistant. Compared with normolipidemic
lean subjects, metabolic syndrome sub-
jects exhibited hypercatabolism of both
LpA-I and LpA-I:A-II with overproduc-
tion of LpA-I (data not shown).
As previously reported (4), fenoﬁ-
brate signiﬁcantly decreased plasma con-
centrations of triglyceride and apoB; it
also signiﬁcantly increased plasma HDL,
HDL2, and HDL3 cholesterol concentra-
tions. Compared with placebo, atorvastatin
signiﬁcantly decreased total cholesterol, tri-
glyceride, LDL cholesterol, and apoB con-
centrations.Homeostasismodelassessment
score did not change signiﬁcantly on either
treatment.
Table 1 gives the kinetic parameters
for LpA-I, LpA-I:A-II, apoA-II, and
apoA-Iafterintervention.Comparedwith
placebo, fenoﬁbrate signiﬁcantly in-
creasedtheproductionratesofLpA-I:A-II
(by 30%; P  0.001) and apoA-II (by
43%; P  0.001). Furthermore, fenoﬁ-
brate increased the FCR of LpA-I:A-II
(and apoA-II) by 16% (P  0.015) com-
pared with placebo, accounting for the
overall 10% (P  0.005) increase in
plasma HDL apoA-I FCR. Collectively,
these kinetic effects accounted for the sig-
niﬁcant increase in concentration of LpA-
I:A-II (10%), apoA-II (23%), and apoA-I
(6%)onfenoﬁbratetreatment.Compared
with placebo, atorvastatin did not signiﬁ-
cantly alter the kinetics or concentrations
of LpA-I, LpA-I:A-II, or apoA-II.
CONCLUSIONS — Our new ﬁnd-
ings show that in subjects with the
metabolic syndrome, fenoﬁbrate signif-
icantlyincreasedtheproductionofboth
LpA-I:A-II and apoA-II, accounting for
the signiﬁcant increase in their plasma
concentrations. These effects were
achieved with no signiﬁcant alteration in
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Regulation of HDL cholesterol transport in metabolic syndrome
2112 DIABETES CARE, VOLUME 32, NUMBER 11, NOVEMBER 2009 care.diabetesjournals.orginsulinresistanceorbodyweight.Bycon-
trast,atorvastatinhadnosigniﬁcanteffect
on any parameters of HDL metabolism.
The fenoﬁbrate data concur with pre-
vious reports showing that this agent in-
creased the production of apoA-I in
mixedhyperlipidemiaandmetabolicsyn-
drome (7). We extend our previous study
(4) by showing that the increased apoA-I
production is restricted to apoA-I in LpA-
I:A-IIparticlesandiscloselycoupledwith
the increased production of apoA-II. This
is consistent with the notion that the gene
expression of both apoA-I and apoA-II is
increased with this peroxisome prolifera-
tor–activated receptor- agonist (8).
The lack of signiﬁcant effect of ator-
vastatin on HDL apoA-I kinetics concurs
with the ﬁndings of a previous study (9).
We extend these ﬁndings to metabolic
syndrome subjects and a wider range of
HDL kinetic measurements including
newdataonapoA-II,LpA-I,andLpA-I:A-
II. We do not conﬁrm data showing that
atorvastatin increases LpA-I and de-
creases LpA-I:A-II concentrations in pa-
tients with coronary heart disease (10).
This may be due to metabolic differences
in study populations and that the coro-
nary heart disease patients studied were
not obese or insulin resistant. It is note-
worthy that rosuvastatin, a more potent
HDL cholesterol–raising agent than ator-
vastatin, decreases LpA-I and LpA-I:A-II
catabolism in subjects with the metabolic
syndrome (11). A recent study by Verges
et al. (12) also showed that rosuvastatin
reduces HDL apoA-I catabolism in type 2
diabetes.Theprecisereasonforthediffer-
ence between atorvastatin and rosuvasta-
tin remains unclear.
Our kinetic ﬁndings could be clini-
cally important. Decreased plasma LpA-I:
A-II concentration is a predictor of
coronary events in population studies
(3) and, in type 2 diabetes, is indepen-
dently associated with angiographic
coronary disease (13). In the FIELD
trial, fenoﬁbrate altered HDL composi-
tion and increased the plasma concen-
tration of A-II and LpA-I:A-II (14). Our
study suggests that this may be due to
increasedproductionofapoA-IIandLpA-
I:A-II particles. The complementary ef-
fects of fenoﬁbrate and atorvastatin on
lipoprotein metabolism, including dis-
parate changes in apoB-100 kinetics (4)
and, as we show here, in the kinetics of
LpA-I and LpA-I:A-II particles, support
the use of combination therapy to opti-
mally regulate dyslipidemia in metabolic
syndrome.
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